Gelonghui, January 3 | Guangshengtang announced that the first phase IIa clinical trial of GST-HG131, an innovative hepatitis B treatment drug of Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., a holding subsidiary, was successfully enrolled for administration on January 3, 2024.
广生堂：乙肝治疗创新药IIa期临床试验首例受试者成功入组
Guangshengtang: The first case of the Phase IIa clinical trial of an innovative drug for hepatitis B treatment was successfully enrolled
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.